-
Sector Analysis
Chronic Kidney Disease Anemia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD Anemia market through 2034. There will be an overall increase in the diagnosed prevalent cases of CKD Anemia in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for CKD Anemia involves the use of ESAs and iron therapies. Significant clinical and environmental unmet needs remain in the CKD Anemia market. The late-stage CKD anemia pipeline consists of 2 agents....
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma Epidemiology Analysis and Forecast to 2034
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] code = C00–C06); the salivary glands (ICD-10 code = C07–C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09–C14); the nose, sinuses, and related structures (ICD-10 code = C30–C31), and...
-
Sector Analysis
Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034. GlobalData estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. The major drivers of growth in the PD market will be the launch of new disease modifying therapies...
-
Sector Analysis
Endometriosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Endometriosis market through 2034. GlobalData estimates the 2024 sales for the endometriosis market at approximately $938.0 million across the 7MM, encompassing the US, the 5EU, and Japan. By 2034, GlobalData expects the overall market to grow at a compound annual growth rate (CAGR) of 10.3% to reach sales of $2.5 billion over the 10-year period. The US market will grow...
-
Sector Analysis
Psoriatic Arthritis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This new set to update and replace the previous psoriatic arthritis market analysis publication, Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028 (January 2020, GDHC186PIDR), which covered the forecast period 2018–28. This new publication covers the psoriatic arthritis market over the forecast period of 2023-33. GlobalData estimated the total psoriatic arthritis market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major GlobalData estimated the value of...
-
Sector Analysis
Multiple Sclerosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Multiple Sclerosis market through 2034. GlobalData estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion...
-
Sector Analysis
Sleep Apnea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Sleep Apnea Therapeutics. In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of sleep apnea, representing a large portion of global cases. Currently, the sleep apnea market is saturated with generic drugs, and the sodium-dependent dopamine transporter (DAT) drug class dominates the approved innovator drugs landscape. The sleep apnea pipeline holds 27 molecules, with one asset in the pre-registration...
-
Sector Analysis
Nontuberculous Mycobacteria (NTM) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook. NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden,...
-
Sector Analysis
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
This report covers the 7 major markets and provides an Excel-based forecast model for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) market through 2032. GlobalData estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%. Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the...
-
Thematic Analysis
FDI Trends in Africa (2025)
Overall, Africa’s share of global FDI remains small, however, investment opportunities across the continent are increasingly viewed as a growth frontier, presenting competitive long-term benefits. Notably, Africa continues to offer higher average profitability on FDI relative to other regions, despite ample structural deficiencies fueling a high-risk premium; this is supported by the fact that the largest 40 companies in Africa have annualized returns of 12.9% in the last year. GlobalData’s FDI Team expects FDI to diversifyaway from traditional, extractive industries...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.